|Stock Name : Jubilant life sciences limited /Tips Open||Buy : 864||Posted Date : Aug 3, 2020|
|Stopless/Horizon : 800/2Months||Target : 980||Results Achieved (Yes/No) :|
Incorporated in 1978,Jubilant Life Sciences limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
Mr. Shyam S Bhartia is the Chairman and Mr. Hari S Bhartia is Co-Chairman and Managing Director of Jubilant Life Sciences Ltd. Promoters own 50.68% of shares.
The company is a Mid Cap company with a market capital of Rs 12422.34 Crore. As on December 31, 2019, the company’s cash and cash equivalents was Rs 687 crore.
Jubilant Life Sciences Limited’swholly owned subsidiary Jubilant Pharma Limited manufactures and supplies Pharmaceuticals and contract manufacturing of Sterile Injectables and Non-sterile
products through 6 USFDA approved manufacturing facilities in the USA, Canada and India.
The Life Science Ingredients segment products are produced through the company’s 5 manufacturing facilities in India.
In the first nine months of fiscal 2020, about 63% of company’s revenue came from the pharmaceuticals segment(manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non -sterile products) and Life Science Ingredientsegment(Specialty Intermediates, Nutritional Products and Life Science Chemicals) contributed 35% of company’s revenue.
For the same period, the pharmaceuticals segment has grown about 7% as compared to same period in previous fiscal; 2019.
Jubilant Life Sciences limited declared an equity dividend of 500.00% amounting to Rs 5 per share for the year ending March 2020.
Jubilant Life Sciences Limitedposted a consolidated sale of Rs 2307.32 Crore for the quarter ended on 31 March of 2020, which was up by 1.20 % from last quarter sales of Rs 2279.89 Crore and down by -1.91 % fromcorresponding period in previous year same quarter sales of Rs 2352.15 Crore
For the first nine months of fiscal 2020, Jubilant Life Sciences limited reported an operating income of Rs 6,763 crore and PAT of Rs 638 crore as against operating income of Rs 6,725 crore and a PAT of Rs 674 crore for first nine months of fiscal 2019.
If you find any mistake please contact the email@example.com. This article is general in nature. It does not constitute a recommendation to buy and sell any stock, and does not take account of your objectives, or your financial situation. Largecapindia has no position in the stocks mentioned.
Largecapindia aim to bring you long term focused research analysis driven by fundamental thanks you.
For More Info : https://www.largecapindia.com